No Evidence of QTc Interval Prolongation With Baxdrostat Treatment: Concentration–QTc Modeling Assessment
ABSTRACT Baxdrostat is a novel, highly potent, selective, competitive inhibitor of human aldosterone synthase currently under development for the treatment of uncontrolled and resistant hypertension and chronic kidney disease. We assessed the risk of QTc‐interval prolongation with baxdrostat using c...
Збережено в:
| Автори: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Wiley
2025-10-01
|
| Серія: | Pharmacology Research & Perspectives |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1002/prp2.70181 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|